These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27489191)

  • 1. Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease.
    Capodanno D; Alberts M; Angiolillo DJ
    Nat Rev Cardiol; 2016 Oct; 13(10):609-22. PubMed ID: 27489191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factor profile and management of cerebrovascular patients in the REACH Registry.
    Röther J; Alberts MJ; Touzé E; Mas JL; Hill MD; Michel P; Bhatt DL; Aichner FT; Goto S; Matsumoto M; Ohman EM; Okada Y; Uchiyama S; D'Agostino R; Hirsch AT; Wilson PW; Steg PG;
    Cerebrovasc Dis; 2008; 25(4):366-74. PubMed ID: 18337635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for the secondary prevention of stroke.
    Toyoda K
    Drugs; 2009; 69(6):633-47. PubMed ID: 19405547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?
    Saposnik G; Goodman SG; Leiter LA; Yan RT; Fitchett DH; Bayer NH; Casanova A; Langer A; Yan AT; ; ;
    Stroke; 2009 Apr; 40(4):1417-24. PubMed ID: 19213947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events.
    Capodanno D; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Jun; 8(4):383-391. PubMed ID: 34374741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
    Capodanno D; Mehran R; Valgimigli M; Baber U; Windecker S; Vranckx P; Dangas G; Rollini F; Kimura T; Collet JP; Gibson CM; Steg PG; Lopes RD; Gwon HC; Storey RF; Franchi F; Bhatt DL; Serruys PW; Angiolillo DJ
    Nat Rev Cardiol; 2018 Aug; 15(8):480-496. PubMed ID: 29973709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factor control and treatment of atherothrombosis. Spain REACH Registry].
    Suárez C; Cairols M; Castillo J; Esmatjes E; Sala J; Llobet X; Palma JC;
    Med Clin (Barc); 2007 Oct; 129(12):446-50. PubMed ID: 17953908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating coronary artery disease in patients with a history of cerebrovascular disease.
    Ducrocq G; Steg PG
    Arch Cardiovasc Dis; 2015 Nov; 108(11):606-11. PubMed ID: 26371986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis.
    Königsbrügge O; Schmaldienst S; Auinger M; Klauser-Braun R; Lorenz M; Tabernig S; Kletzmayr J; Enzenberger B; Eigner M; Hecking M; Siller-Matula JM; Pabinger I; Säemann M; Ay C
    Atherosclerosis; 2020 Apr; 298():1-6. PubMed ID: 32126388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New agents and challenges in the antithrombotic management of arterial diseases].
    Udvardy M; Rák K
    Orv Hetil; 1997 Jan; 138(2):59-65. PubMed ID: 9064617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study.
    Toyoda K; Yasaka M; Iwade K; Nagata K; Koretsune Y; Sakamoto T; Uchiyama S; Gotoh J; Nagao T; Yamamoto M; Takahashi JC; Minematsu K;
    Stroke; 2008 Jun; 39(6):1740-5. PubMed ID: 18388341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
    Lettino M; Leonardi S; De Maria E; Halvorsen S
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):61-70. PubMed ID: 28618904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.
    Patti G; Cavallari I; Andreotti F; Calabrò P; Cirillo P; Denas G; Galli M; Golia E; Maddaloni E; Marcucci R; Parato VM; Pengo V; Prisco D; Ricottini E; Renda G; Santilli F; Simeone P; De Caterina R;
    Nat Rev Cardiol; 2019 Feb; 16(2):113-130. PubMed ID: 30250166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].
    Levi M
    Ned Tijdschr Geneeskd; 2008 Feb; 152(8):423-5. PubMed ID: 18361189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
    Poredos P; Jezovnik MK
    Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.
    Rodriguez F; Cannon CP; Steg PG; Kumbhani DJ; Goto S; Smith SC; Eagle KA; Ohman EM; Umez-Eronini AA; Hoffman E; Bhatt DL;
    Clin Cardiol; 2013 Dec; 36(12):721-7. PubMed ID: 24166484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis--results from the REACH registry.
    Parhofer KG; Zeymer U; Stark RG; Binz C; Schwertfeger M; Bhatt DL; Steg PG; Röther J;
    Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):51-6. PubMed ID: 19834877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications.
    Béjot Y; Zeller M; Lorgis L; Troisgros O; Aboa-Eboulé C; Osseby GV; Giroud M; Cottin Y
    J Neurol Neurosurg Psychiatry; 2013 Mar; 84(3):348-53. PubMed ID: 23152636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke.
    Kim D; Lee SH; Joon Kim B; Jung KH; Yu KH; Lee BC; Roh JK;
    Eur Heart J; 2013 Sep; 34(35):2760-7. PubMed ID: 23729692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome.
    Patti G; Fattirolli F; De Luca L; Renda G; Marcucci R; Parodi G; Perna GP; Andreotti F; Ghiglieno C; Fedele F; Marchionni N
    Biomed Pharmacother; 2021 Aug; 140():111783. PubMed ID: 34102448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.